XERIS BIOPHARMA HOLDINGS, INC. Proceeds from Long-Term Debt Issued
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2025-03-06
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of long-term debt for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of long-term debt for the quarter ending 2023-09-30 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of long-term debt for the quarter ending 2023-06-30 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of long-term debt for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of long-term debt for fiscal 2024 was $0.00.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of long-term debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of long-term debt for fiscal 2022 was $146.21M.
- XERIS BIOPHARMA HOLDINGS, INC. proceeds from issuance of long-term debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 derived: sum of 3 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $48.92M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $48.92M derived: sum of 3 quarters · filed 2025-03-06 | $48.92M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $48.92M derived: sum of 2 quarters · filed 2025-03-06 | $48.92M derived: sum of 3 quarters · filed 2025-03-06 | $48.92M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $48.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $48.92M derived: sum of 2 quarters · filed 2025-03-06 | $48.92M derived: sum of 3 quarters · filed 2025-03-06 | $146.21M 10-K · filed 2025-03-06 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $97.30M 10-Q · filed 2023-11-09 | $97.30M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $97.30M 10-Q · filed 2023-08-08 | $97.30M derived: sum of 3 quarters · filed 2024-03-06 | $97.30M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $97.30M 10-Q · filed 2023-05-09 | $97.30M derived: sum of 2 quarters · filed 2024-03-06 | $97.30M derived: sum of 3 quarters · filed 2024-03-06 | $97.30M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $0.00 derived: sum of 2 quarters · filed 2024-03-06 | $0.00 derived: sum of 3 quarters · filed 2024-03-06 | $0.00 10-K · filed 2024-03-06 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $3.50M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | $3.50M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-11 | $3.50M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $94.84M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $91.34M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |